top of page

ASCO 2024

ASCO is a top organization devoted to advancing cancer care and research. Every year, they hold an important conference where oncology professionals from all over the world come together to share the latest research, clinical advancements, and innovative treatment approaches. The ASCO Annual Meeting covers all aspects of cancer care, including prevention, diagnosis, treatment, and survivorship, and is a must-attend event for those committed to improving the lives of people affected by cancer.

May 31- June 4

12:00 PM ET

McCormick Place • Chicago, IL & Online 

WE CONNECT THE BEST TREATMENTS WITH THE BRIGHTEST MINDS

home_fondo_link_barra.jpg

MEDSIR is a company founded by scientific experts in 2012. We are dedicated to the design and management of strategic clinical trials in oncology, from study conception to the publication of study results.

 

MEDSIR favors a new model for collaborative clinical research in oncology development that aims to combine the highest scientific value with the strategic development of novel cancer treatments, with the final goal of benefiting cancer patients worldwide. Our goal is to generate win-win scenarios for all stakeholders involved in independent clinical research.


 
TOGETHER WE CAN BUILD A BRIGHTER FUTURE

MEDSIR ONCOCLÍNICAS ACADEMY

home_fondo_link_barra.jpg

MEDSIR and Oncoclínicas & Co. teamed up to launch the MEDSIR Oncoclínicas Academy, an educational project aiming to elevate clinical research expertise globally. In the past edition, a group of Medical Oncologists specialized in breast cancer from Brazil, attended a 5-day program in Barcelona, Spain.

 

The hands-on experience in a hospital and the workshops led by experts and KOLs, resulted in an increase of the group’s expertise in the design and management of clinical trials, offering both a scientific and operational perspective while delineating their roles and responsibilities as Principal Investigators.

WHAT WE DO

home_fondo_link_barra.jpg

Our international team of high-level clinicians and research experts are passionate about collaborating with medical oncologists and pharmaceutical companies to develop the best treatments for patients as quickly as possible.

MEDSIR IN NUMBERS

home_fondo_link_barra.jpg

>35
INDUSTRY FUNDERS

>187  
SITES

>59
TRIALS DEVELOPED

>432  
RESEARCH
COLLABORATORS

>862  
IDEAS
GENERATED

>108  
STAFF
DEDICATED

>2455  
PATIENTS
RECRUITED

OUR STUDIES

home_fondo_link_barra.jpg

Some examples of MEDSIR ideas matured into strategic clinical trials.

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

PHERGAIN

BREAST

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

SLLIP

LUNG

Spanish Lung Liquid vs. Invasive biopsy Program (SLLIP)

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

ORPHEUS

PENIS

Phase II Study of the Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

PARSIFAL

BREAST

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

close-up-view-young-female-doctor-writing-medical-charts-with-tablet-office-room.jpg

For any question or suggestion,
we are here for you.

Transparency:
The Ethical Channel for Raising Concerns

bottom of page